{"id":5684,"date":"2004-07-06T10:12:00","date_gmt":"2004-07-06T10:12:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=5684"},"modified":"2022-04-20T11:48:39","modified_gmt":"2022-04-20T11:48:39","slug":"immunomodulatory-therapy-for-inflammatory-bowel-disease","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/de\/professional\/scientific-corner\/immunomodulatory-therapy-for-inflammatory-bowel-disease\/","title":{"rendered":"Immunomodulatory therapy for inflammatory bowel disease"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Kusugami+K&amp;cauthor_id=15622475\">Kazuo Kusugami<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15622475\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ina+K&amp;cauthor_id=15622475\">Kenji Ina<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ando+T&amp;cauthor_id=15622475\">Takafumi Ando<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Hibi+K&amp;cauthor_id=15622475\">Kenji Hibi<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Nishio+Y&amp;cauthor_id=15622475\">Yuji Nishio<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Goto+H&amp;cauthor_id=15622475\">Hidemi Goto<\/a>, J Gastroenterol. 2004 Dec;39(12):1129-37.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Patients with inflammatory bowel disease (IBD) have intestinal and extraintestinal symptoms that can greatly impair their quality of life. They must rely on multiple medications with aminosalicylates, corticosteroids, and purine analogues to control these symptoms. Although decades of clinical experience in IBD management has led to optimized approaches for achieving the induction and maintenance of remission, the disease in some patients is still refractory to conventional medical treatment, or the effectiveness of these drugs can be limited by treatment-related side effects. Significant progress in our understanding of the pathogenesis of IBD has yielded several immunomodulatory approaches with novel biological agents or apparatus, such as cyclosporine, cytoprotective agents, infliximab, and leukocytapheresis. Further immunomodulatoy therapy, aiming at the inhibition of molecular and cellular mediators, is anticipated, in parallel with the clarification of immunoinflammatory pathways in IBD. An additional goal will be to identify factors predictive of response to treatment with each novel immunomodulatory agent or apparatus. This will help provide each patient with optimized and individualized therapy, thereby increasing therapeutic efficacy and reducing possible side effects.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15622475\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/15622475\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Kazuo Kusugami&nbsp;1,&nbsp;Kenji Ina,&nbsp;Takafumi Ando,&nbsp;Kenji Hibi,&nbsp;Yuji Nishio,&nbsp;Hidemi Goto, J Gastroenterol. 2004 Dec;39(12):1129-37. Patients with inflammatory bowel disease (IBD) have intestinal and extraintestinal symptoms that can greatly impair their quality of life. They must rely on multiple medications with aminosalicylates, corticosteroids, and purine analogues to control these symptoms. Although decades of clinical experience in IBD management has [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[147,159,314,424,74,81,91,156,55,185,135,604,306],"class_list":["post-5684","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-clinical-remission","scientific_tags-crohns-disease","scientific_tags-digestive","scientific_tags-gma","scientific_tags-leukocytapheresis","scientific_tags-long-term-outcome","scientific_tags-maintenance","scientific_tags-safety","scientific_tags-steroid-dependent","scientific_tags-steroid-naive","scientific_tags-steroid-refractory","scientific_tags-steroid-tapering-2","scientific_tags-ulcerative-colitis"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Immunomodulatory therapy for inflammatory bowel disease - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-therapy-for-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunomodulatory therapy for inflammatory bowel disease - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Kazuo Kusugami&nbsp;1,&nbsp;Kenji Ina,&nbsp;Takafumi Ando,&nbsp;Kenji Hibi,&nbsp;Yuji Nishio,&nbsp;Hidemi Goto, J Gastroenterol. 2004 Dec;39(12):1129-37. Patients with inflammatory bowel disease (IBD) have intestinal and extraintestinal symptoms that can greatly impair their quality of life. They must rely on multiple medications with aminosalicylates, corticosteroids, and purine analogues to control these symptoms. Although decades of clinical experience in IBD management has [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-therapy-for-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-20T11:48:39+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-therapy-for-inflammatory-bowel-disease\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-therapy-for-inflammatory-bowel-disease\/\",\"name\":\"Immunomodulatory therapy for inflammatory bowel disease - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2004-07-06T10:12:00+00:00\",\"dateModified\":\"2022-04-20T11:48:39+00:00\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-therapy-for-inflammatory-bowel-disease\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunomodulatory therapy for inflammatory bowel disease - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-therapy-for-inflammatory-bowel-disease\/","og_locale":"de_DE","og_type":"article","og_title":"Immunomodulatory therapy for inflammatory bowel disease - Adacyte","og_description":"Kazuo Kusugami&nbsp;1,&nbsp;Kenji Ina,&nbsp;Takafumi Ando,&nbsp;Kenji Hibi,&nbsp;Yuji Nishio,&nbsp;Hidemi Goto, J Gastroenterol. 2004 Dec;39(12):1129-37. Patients with inflammatory bowel disease (IBD) have intestinal and extraintestinal symptoms that can greatly impair their quality of life. They must rely on multiple medications with aminosalicylates, corticosteroids, and purine analogues to control these symptoms. Although decades of clinical experience in IBD management has [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-therapy-for-inflammatory-bowel-disease\/","og_site_name":"Adacyte","article_modified_time":"2022-04-20T11:48:39+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-therapy-for-inflammatory-bowel-disease\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-therapy-for-inflammatory-bowel-disease\/","name":"Immunomodulatory therapy for inflammatory bowel disease - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2004-07-06T10:12:00+00:00","dateModified":"2022-04-20T11:48:39+00:00","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-therapy-for-inflammatory-bowel-disease\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner\/5684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/media?parent=5684"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific_tags?post=5684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}